In this issue of Annals of Surgery, Anthony Polednak of the Connecticut Tumor Registry presents the largest study to date that evaluates a significant sample of patients from various population-based cancer registries in the United States. In this paper, he elucidates the relationship between long-term survival in node-negative breast cancer patients and number of lymph nodes dissected for pathology examination at initial treatment.
This study of 69,543 patients diagnosed in this modern era of pathology techniques (1988 -97) used nine population-based registries in the U.S. National Cancer Institute Surveillance, Epidemiology and End-Results (SEER) Program to evaluate survival outcome for localized invasive node-negative Յ T2 breast cancer. Polednak suggests a high statistical probability for risk of cancer-related death with breast cancer for patients who had only 0, 1 to 3, or 4 to 10 nodes examined compared to those who had 20-plus nodes evaluated pathologically.
As indicated by the author, the study by Sosa et al. 1 of the Johns Hopkins Hospital suggests an association between the extent of the axillary lymph node dissection and overall survival in stage I disease. Of 464 node-negative patients in this analysis with T1 tumors, improved survival was evident among those who had 10-plus nodes dissected versus 1 to 9 nodes removed; the authors could not evaluate mortality from breast cancer versus related comortality due to the small sample size of the study. The more recent analysis by Camp et al. 2 determined that among 290 patients having surgical resections with node dissections for N0 breast cancer at Yale-New Haven Hospital, those with fewer nodes examined (1-9) had superior survival to those with 20-plus nodes examined. This paradoxical outcome is evident following adjustment for prognostic variables in this N0 population. Again, the small sample size and infrequent breast cancer-specific death rates were insufficient to allow separate analysis with regard to breast cancer mortality.
The more recent analysis by Moorman et al. 3 
at Duke
University Medical Center refuted both the study by Sosa et al. 1 and that of Camp et al. 2 The Duke investigators suggested that there is no relationship between breast cancerspecific mortality and the number of lymph nodes examined. Among 911 patients diagnosed between 1985 and 1993 for T1 and T2 node-negative invasive tumors, the hazard ratio for 1 to 19 nodes versus 20-plus nodes examined was 0.99. The current study by Polednak attempts to clarify the inexplicable diversity of results for these smaller studies by using a large patient sample size obtained from a high-quality population-based cancer registry system (SEER). In the excellent analysis by Greco et al. 4 for the 5-year follow-up study of T1 and T2, N0 clinically node-negative invasive carcinomas treated without axillary dissection, there was a fourfold greater risk of nodal relapse for T2 carcinomas (34%) versus T1 lesions (9%). The authors determined that the avoidance of axillary dissection had a negligible impact on outcome for patients with small tumors. Polednak suggests that the adjusted hazard ratio (HR) for T1a/T1b tumors in the nine SEER registries was 1.0. This HR increased in proportion to tumor size: HR ϭ 2.1 for T1c tumors (1.1-2.0 cm) and HR ϭ 4.5 for T2 tumors (2.1-5.0 cm). Histologically positive nodes increased with enlarging index tumor size; the outcomes reported by Polednak are consistent with an increasing risk of cancer-related deaths with increasing tumor size.
Our data from the Hospital Association of Rhode Island and the Tumor Registry at Bay State Medical Center (Springfield, MA) confirm that among 2,185 invasive tumors 1 cm in diameter or smaller, small tumor size (T1a/ T1b) did not affect survival. 5, 6 In two studies of T1a and T1b lesions, nodal status significantly influenced diseasefree survival, even for these minimally invasive cancers. Node positivity was evident in 18.2% of patients undergoing axillary dissection for these minimally invasive lesions (9.8% for T1a, 19.4% for T1b lesions, P ϭ .01). 5 Moreover, nodal status was the most powerful determinant of survival in breast cancer patients with these small invasive lesions.
In a review 7 of the National Cancer Data-Base (NCDB) of the American College of Surgeons' Commission on Cancer, data from 547,847 women with stage I and stage II breast cancer treated in U.S. hospitals from 1985 to 1995 were analyzed. The 10-year relative survival for clinical stage I disease treated with partial mastectomy and axillary node dissection was 85% (n ϭ 1,242) versus 66% (n ϭ 1,684) for comparable women in whom axillary node dissection was omitted. Breast conservation surgery with axillary node dissection followed by radiation for stage I disease resulted in 94% (n ϭ 5,469) 10-year relative survival, compared with 85% in patients (n ϭ 1,284) treated without axillary node dissection. The addition of combination radiation and chemotherapy to breast conservation with axillary node dissection for stage I disease resulted in a 10-year relative survival rate of 86% (n ϭ 2,800) versus 58% (n ϭ 512) for those in whom axillary node dissection was omitted. In contrast, women with stage II (N1) disease treated with breast conservation and axillary node dissection followed by radiation and chemotherapy had a 72% 10-year relative survival rate. 7 These data confirm that 10-year survival rates were significantly worse in this NCDB population when axillary node dissection was omitted. This adverse survival effect was not considered to be solely derived from an understaging of the patients; axillary dissection possibly had a (direct) therapeutic effect.
The more recent application of sentinel lymph node mapping, introduced by Morton for melanoma in 1992, has had a major impact on the therapeutic management of stage I and II breast disease. Two important clinical trials are being conducted to compare sentinel node mapping without axillary clearance to that of levels I/II axillary dissection. These trials, being conducted by the University of Vermont/National Surgical Adjuvant Breast and Bowel Project, will focus primarily on node-negative disease. 8 Moreover, the American College of Surgeons Clinical Oncology Trial Group is conducting an extended study for node-positive (N1) breast cancer patients, confirmed at sentinel node mapping, for randomization between standard axillary dissection and omission of this definitive procedure. These trials will establish the value of sentinel node surgery alone to provide the therapeutic index expected with axillary dissection; sentinel node biopsy can be done without the morbidity associated with standard axillary dissection. Endpoints of these clinical trials will be breast cancer-specific survival, local-regional control, and surgical morbidity. Figure 1 shows a compilation of six prospective randomized clinical trials comparing regional node dissection completed synchronously with definitive therapy of the index breast tumor versus delayed nodal therapy at the time of evident nodal recurrence in the axilla. These six trials 9 -14 confirm improved survival rates in the groups treated with initial axillary node dissections; this effect was independent of systemic adjuvant therapy. The relative reduction in survival by omission of the initial axillary dissection ranged from 7% to 46%. Three of these trials reached statistical significance. Included in this figure is the prospective analysis of the NCDB data completed for stage I disease that includes segmental mastectomy with or without axillary nodal dissection. This analysis extends this surgical modal-ity with the addition of adjuvant therapies (either radiation therapy or its combination with chemotherapy). These six prospective randomized trials and data from the NCDB suggest a survival benefit for patients treated with initial axillary node dissection. These results have been previously emphasized by Orr 15 in a Bayesian meta-analysis.
The association of an enhancement for breast cancerspecific survival may result from the more extensive axillary dissection and may in part explain Polednak's results. The purposes of regional node dissection at the time of index breast tumor excision include: 1) a more accurate AJCC staging of the N0 axilla; 2) an improvement in breast cancer-specific survival; and 3) an enhancement of local-regional control of disease. The high reliability of the sentinel node mapping procedure will further reduce the false-negative and false-positive staging rates that are evident with routine axillary dissections that do not use this technique. Clinical evaluation of the histologic status of the axilla is notoriously unreliable; however, no long-term data currently exist for this evolving technology relative to survival outcomes.
In Polednak's study, pathologic analysis for nodal disease without the highly accurate benefit of sentinel node mapping suggests that the more comprehensive axillary nodal dissection (Ն20 nodes) to confirm node-negative disease performed synchronous with treatment of the index tumor provides therapeutic benefit by removing occult node-positive disease. Thus, the patients with analysis of 0, 1 to 3, or 4 to 10 nodes were likely understaged. A more plausible explanation of Polednak's outcomes is that the more comprehensive axillary dissection (Ն20 nodes) more accurately provided correct histologic staging (true-negative status) of the clinical node-negative (cN0) axilla. Further, those patients with node-positive (N1) disease confirmed histologically will more likely receive systemic adjuvant therapies, which are known to have a beneficial effect on therapeutic We hope that the direct therapeutic effect of axillary dissection can be determined with the Z10/Z11 protocols of the American College of Surgeons Oncology Trials Group, which randomize these N1 patients to axillary dissection versus its omission. As an approximately 97% accuracy is currently evident for sentinel node mapping of the N0 axilla, this approach will almost certainly replace other considerations that predict survival, including an estimate of the number of nodes procured and examined histopathologically following routine axillary node dissection.
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